SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Tsolaki M) "

Search: WFRF:(Tsolaki M)

  • Result 41-50 of 159
Sort/group result
   
EnumerationReferenceCoverFind
41.
  •  
42.
  •  
43.
  • Delvenne, A., et al. (author)
  • Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology
  • 2023
  • In: Alzheimers & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 19:3, s. 807-820
  • Journal article (peer-reviewed)abstract
    • Background Suspected non-Alzheimer's disease pathophysiology (SNAP) is a biomarker concept that encompasses individuals with neuronal injury but without amyloidosis. We aim to investigate the pathophysiology of SNAP, defined as abnormal tau without amyloidosis, in individuals with mild cognitive impairment (MCI) by cerebrospinal fluid (CSF) proteomics. Methods Individuals were classified based on CSF amyloid beta (A beta)1-42 (A) and phosphorylated tau (T), as cognitively normal A-T- (CN), MCI A-T+ (MCI-SNAP), and MCI A+T+ (MCI-AD). Proteomics analyses, Gene Ontology (GO), brain cell expression, and gene expression analyses in brain regions of interest were performed. Results A total of 96 proteins were decreased in MCI-SNAP compared to CN and MCI-AD. These proteins were enriched for extracellular matrix (ECM), hemostasis, immune system, protein processing/degradation, lipids, and synapse. Fifty-one percent were enriched for expression in the choroid plexus. Conclusion The pathophysiology of MCI-SNAP (A-T+) is distinct from that of MCI-AD. Our findings highlight the need for a different treatment in MCI-SNAP compared to MCI-AD.
  •  
44.
  • Elvsashagen, T, et al. (author)
  • The genetic architecture of human brainstem structures and their involvement in common brain disorders
  • 2020
  • In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 11:1, s. 4016-
  • Journal article (peer-reviewed)abstract
    • Brainstem regions support vital bodily functions, yet their genetic architectures and involvement in common brain disorders remain understudied. Here, using imaging-genetics data from a discovery sample of 27,034 individuals, we identify 45 brainstem-associated genetic loci, including the first linked to midbrain, pons, and medulla oblongata volumes, and map them to 305 genes. In a replication sample of 7432 participants most of the loci show the same effect direction and are significant at a nominal threshold. We detect genetic overlap between brainstem volumes and eight psychiatric and neurological disorders. In additional clinical data from 5062 individuals with common brain disorders and 11,257 healthy controls, we observe differential volume alterations in schizophrenia, bipolar disorder, multiple sclerosis, mild cognitive impairment, dementia, and Parkinson’s disease, supporting the relevance of brainstem regions and their genetic architectures in common brain disorders.
  •  
45.
  •  
46.
  •  
47.
  • Kaufmann, Tobias, et al. (author)
  • Common brain disorders are associated with heritable patterns of apparent aging of the brain
  • 2019
  • In: Nature Neuroscience. - : Nature Publishing Group. - 1097-6256 .- 1546-1726. ; 22:10, s. 1617-
  • Journal article (peer-reviewed)abstract
    • Common risk factors for psychiatric and other brain disorders are likely to converge on biological pathways influencing the development and maintenance of brain structure and function across life. Using structural MRI data from 45,615 individuals aged 3-96 years, we demonstrate distinct patterns of apparent brain aging in several brain disorders and reveal genetic pleiotropy between apparent brain aging in healthy individuals and common brain disorders.
  •  
48.
  • Kurbatova, N., et al. (author)
  • Urinary metabolic phenotyping for Alzheimer's disease
  • 2020
  • In: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 10:1
  • Journal article (peer-reviewed)abstract
    • Finding early disease markers using non-invasive and widely available methods is essential to develop a successful therapy for Alzheimer's Disease. Few studies to date have examined urine, the most readily available biofluid. Here we report the largest study to date using comprehensive metabolic phenotyping platforms (NMR spectroscopy and UHPLC-MS) to probe the urinary metabolome in-depth in people with Alzheimer's Disease and Mild Cognitive Impairment. Feature reduction was performed using metabolomic Quantitative Trait Loci, resulting in the list of metabolites associated with the genetic variants. This approach helps accuracy in identification of disease states and provides a route to a plausible mechanistic link to pathological processes. Using these mQTLs we built a Random Forests model, which not only correctly discriminates between people with Alzheimer's Disease and age-matched controls, but also between individuals with Mild Cognitive Impairment who were later diagnosed with Alzheimer's Disease and those who were not. Further annotation of top-ranking metabolic features nominated by the trained model revealed the involvement of cholesterol-derived metabolites and small-molecules that were linked to Alzheimer's pathology in previous studies.
  •  
49.
  • Lawlor, B., et al. (author)
  • NILVAD protocol: A European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
  • 2014
  • In: BMJ Open. - : BMJ Publishing Group. - 2044-6055. ; 4:10
  • Journal article (peer-reviewed)abstract
    • Introduction: This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer's disease (AD) in a phase III study that will run for a period of 82 weeks with a treatment period of 78 weeks. Methods and analysis: Adult patients, males and females over 50 years with mild-to-moderate AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease and Related Disorders Association (NINCDSADRDA) criteria, will be included in the study. It aims to recruit a total of 500 patients with AD; 250 in the nilvadipine group and 250 in the placebo group. Participants will be randomised to receive nilvadipine, an 8 mg overencapsulated, sustained release capsule, or a matching overencapsulated placebo (sugar pill) for a period of 78 weeks of treatment. The primary efficacy outcome measure in this study is the change in cognitive function as assessed by the Alzheimer's disease Assessment Scale (ADASCog 12) from baseline to the end of treatment duration (78 weeks). There are two key secondary outcome measures, the Clinical Dementia Rating Scale Sum of Boxes (CDRsb) and the Disability Assessment for Dementia (DAD). If a statistically significant effect is seen in the primary outcome, CDRsb will be considered to be a coprimary end point and only the DAD will contribute to the secondary outcome analysis. Ethics and dissemination: The study and all subsequent amendments have received ethical approval within each participating country according to national regulations. Each participant will provide written consent to participate in the study. All participants will remain anonymised throughout and the results of the study will be published in an international peerreviewed journal. Trial registration number EUDRACT Reference Number: 201200276427.
  •  
50.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 41-50 of 159
Type of publication
journal article (157)
conference paper (2)
Type of content
peer-reviewed (150)
other academic/artistic (9)
Author/Editor
Tsolaki, M (121)
Soininen, H (72)
Mecocci, P (66)
Lovestone, S (65)
Vellas, B (60)
Simmons, A. (46)
show more...
Kloszewska, I (43)
Westman, E (41)
Wahlund, LO (39)
Tsolaki, Magda (35)
Blennow, Kaj, 1958 (34)
Zetterberg, Henrik, ... (30)
Scheltens, P (29)
Spenger, C (28)
Scheltens, Philip (26)
Freund-Levi, Yvonne, ... (26)
Visser, Pieter Jelle (25)
Vandenberghe, R (24)
Lleó, A. (24)
Soininen, Hilkka (23)
Engelborghs, S. (23)
Teunissen, Charlotte ... (20)
Visser, PJ (20)
Wallin, Anders, 1950 (19)
Hampel, H. (19)
Visser, P. J. (19)
Hampel, Harald (19)
Pasquier, F (18)
Nobili, F (17)
Lleó, Alberto (17)
Engelborghs, Sebasti ... (17)
Popp, J (17)
Sleegers, K (17)
Parnetti, L (16)
Froelich, L (16)
Proitsi, P (16)
Boada, M. (15)
Ingelsson, Martin (15)
Graff, C (15)
Verhey, F (15)
Aarsland, D (14)
Vandenberghe, Rik (14)
Wiltfang, J (14)
Frisoni, GB (14)
Lovestone, Simon (14)
Van Broeckhoven, C (14)
Peters, O. (13)
Muehlboeck, JS (13)
Frisoni, Giovanni B. (13)
de Mendonça, A (13)
show less...
University
Karolinska Institutet (138)
University of Gothenburg (51)
Örebro University (27)
Lund University (25)
Uppsala University (20)
Stockholm University (11)
show more...
Umeå University (4)
Linköping University (3)
Jönköping University (1)
show less...
Language
English (159)
Research subject (UKÄ/SCB)
Medical and Health Sciences (85)
Natural sciences (4)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view